Disease/Infection News

RSS

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.

19 Apr 2010

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Anne-Mette R. Grønvold has through her doctoral research shown that resistance to antibiotics is on the increase in intestinal bacteria in animals as a direct result of antibiotic treatments. The antibiotics also alter the composition of bacteria in the intestines.

19 Apr 2010

Researchers reveal new switch to Salmonella bacteria: Science

A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published today in the journal Science.

19 Apr 2010

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results in which a Hydrofiber dressing containing ionic silver was observed to conform more closely to a porcine tissue surface in a shallow wound model than did certain silver-containing foam dressings following hydration.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.

17 Apr 2010

700 scientists to present new information on smell and taste at AChemS 32nd annual meeting

The Association for Chemoreception Sciences (AChemS), a US-based scientific organization, is holding its 32nd annual meeting. About 700 scientists are gathering to present new information on the role of smell and taste in disease, nutrition and social interactions in humans as well as animals. Smell and taste play essential roles in our daily lives. These chemical senses serve as important warning systems, alerting us to the presence of potentially harmful situations or substances, including gas leaks, smoke, and spoiled food.

17 Apr 2010

WHO issues guidance on ash cloud from Iceland volcanic explosion

The ash cloud from the volcanic explosion in Iceland contains fine particles, similar to those emitted from other sources of particulate matter (PM); but as long as ash remains in the upper atmosphere, there will not likely be an increased risk of health effects, according to WHO.

17 Apr 2010

Project to integrate data from climate modelling, disease forecasting systems for predicting epidemics

Researchers across 13 European and African research institutes will work together to integrate data from climate modelling and disease forecasting systems to predict the likelihood of an epidemic up to six months in advance. The research, funded by the European Commission Seventh Framework programme, will focus on climate and disease in Senegal, Ghana and Malawi and aims to give decision makers the necessary time to deploy intervention methods to help prevent large scale spread of diseases such as Rift Valley Fever and malaria.

17 Apr 2010

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

24 weeks of treatment could be sufficient to cure between 93 and 100% of treatment-na-ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to Telaprevir (TVR) with Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

17 Apr 2010

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

Governor Edward G. Rendell today announced that $1 million from the American Recovery and Reinvestment Act has been awarded to Pennsylvania to prevent and manage chronic disease in older citizens.

17 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus and progression to cancers other than hepatocellular carcinoma.

16 Apr 2010

International study evaluates new class of drugs for treating primary biliary cirrhosis

Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.

16 Apr 2010

Geographic regions with different kinds of birds and mammals could be a source of pathogens

If your home region has a hot, wet climate and a lot of different kinds of birds and mammals living in it, there's a really good chance the region will also contain numerous kinds of pathogens that cause human diseases.

16 Apr 2010

Research shows general health spending offers better return in most affected areas

Eradicating smallpox was one of the greatest human accomplishments of the 20th century, but new research shows initiatives of this kind are not as good a use of health dollars as people might think.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

UDH to participate in Abbott's new PLEX-ID BPEP

Abbott today announced that the Utah Department of Health is one of five sites in the United States to participate in Abbott's new PLEX-ID Biopreparedness Evaluation Program, which involves Abbott, the Association of Public Health Laboratories and five state public health labs.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

Disease/Infection News

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Researchers reveal new switch to Salmonella bacteria: Science

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

700 scientists to present new information on smell and taste at AChemS 32nd annual meeting

WHO issues guidance on ash cloud from Iceland volcanic explosion

Project to integrate data from climate modelling, disease forecasting systems for predicting epidemics

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

FDA approves BioAlliance Pharma's Oravig for OPC

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

International study evaluates new class of drugs for treating primary biliary cirrhosis

Geographic regions with different kinds of birds and mammals could be a source of pathogens

Research shows general health spending offers better return in most affected areas

Results of study comparing REMICADE to azathioprine for Crohn's disease published

UDH to participate in Abbott's new PLEX-ID BPEP

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News